| |
Recent Blog Posts
From
Luck-e-Strike
What are the Economic Costs of Smoking
What We Already Know About Smoking
FROM LUCK-E-STRIKE
Today there is some controversy
regarding E-Cigarettes. It seams the FDA is being pushed to regulate
E-Cigarettes. Here at Luck e Strike we market solely to existing tobacco
smokers who want a cheaper and healthier alternative to tobacco smoking.
I do not believe the FDA or any other non-smoking advocate group can
successfully argue that E-Cigarettes are more harmful than traditional
tobacco cigarettes but the FDA has done a short study and found traces
of some carcinogen chemicals. All far lower than what would be
considered harmful amounts but they have to start somewhere to justify
a more longer term study, which they probably will never do. Their study
is so flawed below you will be-able to read rebuttals to their ridicules
claims
So now were back to the private
sector performing their own studies which will generally take some years
and a couple hundred thousand case study people. Now they can submit
their findings to the FDA which will look at their studies and determine
if they carry any merit. Then if the FDA feels that the private sector
studies are OK they will then want to perform their own case studies to
see if they will come up with the same results and then vote on whether
to pass for consumer consumption or not. This whole process an take up
to 5 yrs.
We feel they are more
driven by big tobacco companies and lost tax revenue than anything else.
What they are failing to consider is the overall health benefits to our
current failing health care system. They want to supply health care to
all our citizens but can not figure out how to pay for it. Well FDA here
is a novel thought why not reduce some of the most costly procedures our
hospitals are performing everyday. Yes we are talking about all the
cancer, respiratory and coronary artery problems that regular tobacco
cigarettes contribute to. These procedures are so costly that today we
have hospitals that specialize in one or the other.
We are making great progress in
reducing the number of Americans who smoke and the number of Americans
who die prematurely due to tobacco use. However, the financial burden on
individuals and society as a result of smoking remain immense.
During 1997 through 2001,
smoking cost the US approximately $167 billion annually. This figure
includes about $92 billion from loss of productivity due to premature
death and $75 billion in smoking-related health care costs. Utah incurs
about $273 million each year in direct medical expenses and $257 million
in lost productivity.
Nationally, one in five of all
deaths are related to tobacco use. It kills more than 430,000 people
every year--more than AIDS, alcohol, drugs abuse, automobile accidents,
murders, suicides, and fires combined. Five million years of
potential life is lost every year due to premature death caused
by tobacco use, medical costs total more than $50 billion annually, and
indirect cost another $50 billion.
Of the 4,000 or more different
chemicals present in cigarette smoke, 60 are known to cause cancer and
others to cause cellular genetic mutations that can lead to cancer.
(Source
Link)
CDC
What We
Already Know About
Cigarette
smoking
The World Health Organization
WHO) has named tobacco one of the greatest
public health threats of the twenty-first century. As of 1999, more
than one billion people worldwide smoke, and 3.5 million people are
expected to die from causes directly related to tobacco use. This
death rate is expected to rise to 10 million by the year 2030. Seventy
percent of these deaths will occur in developing countries where the
proportion of smokers is growing, particularly among women. Calling
tobacco "a global threat," WHO says these figures do not include the
enormous physical, emotional, and economic costs associated with
disease and disability caused by tobacco use.
Nationally, one in five of all deaths are
related to tobacco use. It kills more than 430,000 people every
year--more than AIDS, alcohol, drugs abuse, automobile accidents,
murders, suicides, and fires combined. Five million years of
potential life is lost every year due to premature death caused
by tobacco use, medical costs total more than $50 billion annually,
and indirect cost another $50 billion.
Of the 4,000 or more different chemicals
present in cigarette smoke, 60 are known to cause cancer and others to
cause cellular genetic mutations that can lead to cancer. Cigarette
smoke contains nicotine--a highly addictive chemical--tars,
nitrosamines, and polycyclic hydrocarbons, all of which are
carcinogenic. It also contains carbon monoxide which, when inhaled,
interferes with transportation and utilization of oxygen throughout
the body.
Scientific evidence has proven that smoking
can cause cancer of the lung, larynx, esophagus, mouth, and bladder;
cardiovascular disease; chronic lung ailments; coronary heart disease;
and stroke. It also prohibits the healing of peptic ulcers, in
addition to promoting recurrence of the condition. Smokeless tobacco
has equally deadly consequences. When cigarette smoke is inhaled, the
large surface area of the lung tissues and alveoli quickly absorb the
chemical components and nicotine. Within one minute of inhaling, the
chemicals in the smoke are distributed by the bloodstream to the
brain, heart, kidneys, liver, lungs, gastrointestinal tract, muscle,
and fat tissue. In pregnant women, cigarette smoke crosses the
placenta and may effect fetal growth.
Cardiovascular disease, or diseases of the
blood vessels and heart, includes stroke, heart attack, peripheral
vascular disease, and aortic aneurysm. In 1990 in the United States,
one fifth of all deaths due to cardiovascular disease were linked to
smoking. Specifically, 179,820 deaths from general cardiovascular
disease, 134,235 deaths from heart disease, and 23,281 deaths from
cerebrovascular disease (stroke) were directly linked to smoking. In
addition, researchers have noted a strong dose-response relationship
between the duration and extent of smoking and the death rate from
heart disease in men under 65.The more one smokes, the more one is
likely to develop heart disease. Researchers have also seen a similar
trend in women. Calling tobacco "a global threat," WHO says these
figures do not include the enormous physical, emotional, and economic
costs associated with disease and disability caused by tobacco use.
Nationally, one in five of all deaths are
related to tobacco use. It kills more than 430,000 people every
year--more than AIDS, alcohol, drugs abuse, automobile accidents,
murders, suicides, and fires combined. Five million years of
potential life is lost every year due to premature death caused
by tobacco use, medical costs total more than $50 billion annually,
and indirect cost another $50 billion. Smoking causes 85% of all lung
cancers, and 14% of all cancers--among them cancers of the mouth,
pharynx (throat), larynx (voice-box), esophagus, stomach, pancreas,
cervix, kidney, ureter, and bladder. More than 171,500 new diagnoses
were expected in 1998. Other environmental factors add to the
carcinogenic qualities of tobacco. For example, alcohol consumption
combined with smoking accounts for three-quarters of all oral and
pharyngeal cancers. Also, persons predisposed genetically to certain
cancers may develop cancer more quickly if they smoke. Only 14% of
lung cancer patients survive five years after diagnosis.
Smoking is the leading cause of lung disease
in the United States. Among the direct causes of death are pneumonia,
influenza, bronchitis, emphysema, and chronic airway obstruction.
Smoking increases mucus production in the airways and deadens the
respiratory cilia, the tiny hairs that sweep debris out from the
lungs. Without the action of the cilia, bacteria and inhaled particles
from cigarette smoke are free to damage the lungs.
In the smaller airways of the lungs--the tiny
bronchioles that branch off from the larger bronchi--chronic
inflammation is present in smokers which causes airways to constrict
causing cough, mucus production, and shortness of breath. Eventually,
this inflammation can lead to chronic obstructive pulmonary disease (COPD),
a condition in which oxygen absorption by the lungs is greatly
reduced, severely limiting the amount of oxygen transported to body
tissues.
For the 40 years prior to 1987, breast cancer
was the leading cause of cancer deaths among women in the United
Smoking leads to cardiovascular disease in a
number of ways. Smoking damages the inside of the blood vessels,
initiating changes that lead to atherosclerosis, a disease
characterized by blood vessel blockage. In 1987, lung cancer took the
lead. As well as increased risk of cancer and cardiovascular disease,
women smokers are at increased risk of osteoporosis (a disease in
which bones become brittle and vulnerable to breakage), cervical
cancer, and decreased fertility. Pregnant women have increased risk
for spontaneous abortion, premature separation of the placenta from
the uterine wall (a life-threatening complication for mother and
fetus), placenta previa (in which the placenta implants much lower in
the uterus than normal, which may lead to hemorrhage), bleeding during
pregnancy, and premature rupture of the placental membranes (which can
lead to infection). Infants born to women who smoke during pregnancy
are at increased risk for low birth weight (18,600 cases annually),
and other developmental problems. In men, smoking lowers testosterone
levels, and appears to increase male infertility.
Numerous other health problems are caused by
smoking such as poor circulation in the extremities due to constricted
blood vessels. This not only leads to constantly cold hands and feet;
it often requires amputation of the lower extremities. Smoking also
deadens the taste buds and the receptors in the nasal epithelium,
interfering with the senses of taste and smell, and may also
contribute to periodontal disease.
References http://www.faqs.org/health/topics/72/Cigarette-smoking.htm
Do we really have to go on. How does keeping
the status quo a better alternative. E-Cigarettes may not be perfect but
for every consumer that switches we can reduce overall health costs and
help insure other needy people.
You can see which side of the fence we sit. And
below you can read other blogs and articles of responsible reasoning.
But you need to be the judge for your self so if you google e-cigarette
news you can find other articles from people who have a different
opinion. PS most articles carry a post your comment area make sure you
read the general publics opinion as well you may be surprised.
So what is the big deal over electronic
cigarettes? Why would any public health organization or quit smoking
group be against a product that doesn’t produce smoke? Why would the
FDA be so determined to undermine the electronic cigarette’s current
success by misleading the public with false conclusions from it’s
testing?
It all started when smoking was found to kill
people. Then, the pharmaceutical companies found there was money to be
made by selling smokers nicotine in hopes to get them off of smoking.
These companies were required to get approval from the FDA to market
their quit smoking products. Approval means
huge sums of money paid to the FDA.
Many public health organizations and quit
smoking groups get at least some of their money from pharmaceutical
companies. Whether this was the driving factor or it was their hope of
less people dieing from smoking, these crusaders against smoking got
motivated. Not only did they recommend smokers quit smoking (often by
using a pharmaceutical product) they demonized smokers. They did a
good job. There is little tolerance in America today for a smoker.
Enter the electronic cigarette. This simple
little device threatens to turn the tables of years of hate speech. It
is much harder to hate an action of someone else if that actions hurts
only the user…..or nobody at all. Some still will, but the ads against
e-smoking won’t have the same impact as those against tobacco smoking.
Left unchecked, the electronic cigarette
could put a dent in the tobacco market, a dent in the pharmaceutical
nicotine market, and give pause to those who feel hate towards
smokers. It is obvious the pharmaceutical companies, the tobacco
companies, the public health organizations, and the FDA would rather
avoid some, if not all, of these outcomes.
This is about a habit and it’s social
acceptance. Certain groups want to maintain the status quo. We want a
practical alternative to the issue of smoking.
The current litigation between two electronic
cigarette suppliers and the FDA has everyone in a tailspin. It
certainly did not help that the FDA openly misled the public into
believing that the electronic cigarette is as (or more) dangerous than
tobacco cigarettes. Many medical health professionals have weighed in
on this noting the following:* Dr.
Elizabeth Whelan, president of the American Council on Science and
Health, called the FDA statement “distorted, incomplete, and
misleading. She also noted that “products of combustion cause cancers,
cardiovascular disease and lung disease, and more.”
* Dr. Joel Nitzkin, MD, MPH, DPA, FACPM,
Chair, Tobacco Control Task Force, American Association of Public
Health Physicians stated that “We have every reason to believe the
hazard posed by electronic cigarettes would be much loweigarettes), we
would eventually reduce the US death toll from more than 400,000 a
year to less than 4,000, maybe as low as 400.”
* Michael Siegel, a physician, researcher and
professor at the Boston University School of Public Health noted that
“What the FDA and anti-smoking groups are doing is committing medical
malpractice on a massive scale: on a population basis. They are
essentially condemning 100,000-plus consumers to a return to the most
deadly known conindividuals have reported a tremendousInstead
improvement in their health since switching to electronic cigarettes.”
Just for the record, all of the above public
health officials are anti-smoking advocates.
The FDA and many anti-smoking groups are
calling for the electronic cigarette to be pulled from the market on
the basis that it is not a proven quit smoking device. The
Electronic
Cigarette Association (ECA) President
Matt Salmon, former US Congressman from Arizona, noted in a letter to
Congress that the ECA “acknowledges the health risks of cigarette
smoking and advocates that smokers quit. But we also recognize the
struggles that many have in quitting and who are looking for a more
convenient and better alternative to tobacco cigarettes. While some of
our customers have reported using our devices to help them quit
smoking by slowing reducing the nicotine delivery in our products, it
is important to note that our member companies do not market their
e-cigarettes as smoking cessation products nor make any such claims.”
What is most important is the idea of claims.
The FDA was formally named in 1930, and the
“FDA’s modern regulatory functions began with
the passage of the 1906 Pure Food and Drugs Act, a law a
quarter-century in the making that prohibited interstate commerce in
adulterated and misbranded food and drugs.”
The original act had huge issues mainly that
“False therapeutic claims for patent medicines were basically
unregulated, as the manufacturer had only to show that he personally
believed that his remedy worked to avoid prosecution, and standards
for food purity and content were nonexistent.”
In 1938, after the
1937
Elixir Sulfanilamide Incident, where
the SE Massengil Company created an elixir containing diethylene
glycol as the base ingredient was given to children with strep which
led to painful deaths, the Federal Food, Drug and Cosmetic Act was put
into place. Following, came several examples of “incidents” and “near
incidents” that lead for further revision of the Act.
But the question that lies at the heart of
this debate is the electronic cigarette liquid really a “new drug” and
is the electronic cigarette hardware really a “medical device”?
According to the FDA’s definition of “new drug”, they state that the
definition of a drug includes
“intended for use in the diagnosis, cure,
mitigation, treatment, or prevention of disease in man or other
animals” To put this into comparison
with other products on the market that do not require FDA approval,
let us look at dietary supplements.
Currently, the FDA does not regulate dietary
supplements. Those products do not have to be FDA approved for safety,
however, they can be recalled by the FDA if there are enough
complaints. The only responsibility the manufacturer holds is that
“Manufacturers must make sure that product label
information is truthful and not misleading.”
Keeping this idea in mind that products can
be on the market without FDA regulation, lets look at nicotine.
Currently, there is nothing contained within the FDA website referring
to nicotine. However, there is a plant out there that has many of the
same effects as nicotine and that is lobelia inflata which IS
specifically mentioned on the FDA website. The FDA notes in
Sec. 310.544 Drug products containing active
ingredients offered over-the-counter (OTC) for use as a smoking
deterrent, that “Any OTC drug product
that is labeled, represented, or promoted as a smoking deterrent is
regarded as a new drug within the meaning of section 201(p) of the
Federal Food, Drug, and Cosmetic Act (the act), for which an approved
application or abbreviated application under section 505 of the act
and part 314 of this chapter is required for marketing.” But what
happens if these claims are not to be made and the product clearly
states that this product has not been evaluated by the FDA?
Now, let’s review what the FDA considers a
“medical device”.
The term “device”… means an instrument,
apparatus, implement, machine, contrivance, implant, in vitro reagent,
or other similar or related article, including any component, part, or
accessory, which is–
(1) recognized in the official National Formulary, or the United
States Pharmacopeia, or any supplement to them,
(2) intended for use in the diagnosis of disease or other conditions,
or in the cure, mitigation, treatment, or prevention of disease, in
man or other animals, or
(3) intended to affect the structure or any function of the body of
man or other animals, and which does not achieve its primary intended
purposes through chemical action within or on the body of man or other
animals and which is not dependent upon being metabolized for the
achievement of its primary intended purposes.
For comparison purposes, we need to look at
tobacco vaporizers. Tobacco vaporizers are currently not FDA
regulated. Many of the vaporizers currently sold on the market today,
carry the warning that the vaporizer is not approved for
medical-therapeutic purposes. If the electronic cigarette is simply a
vaporizer, which is it as it uses no combustion, and there are
currently hundreds of other products on the market that vaporize
tobacco to deliver nicotine into the body, and those are not
classified as “medical devices”, then these smaller, more compact
versions should fall into the same category as the larger versions,
like the
Volcano.
If the electronic cigarette liquid uses
ingredients that are found in traditional tobacco cigarettes, all
ingredients are FDA approved as generally safe for consumption, and
the supplier placing the product on the market is not making any
claims, then based on the above arguments, the electronic cigarette
liquid is not a “new drug” and therefor does not need to be approved
by the FDA. This would also lead to the conclusion that if the liquid
itself is not a “new drug”, then the hardware itself is not a “medical
delivery device”.
Instead stands firm that smokers should have
the option to smoke something other than tobacco cigarettes. There
should be regulations and those regulations should be put forth by a
regulatory body who understands that tobacco harm reduction products
have a place in the free market.
Below is the summary of the Technical Review
and Analysis of FDA Report: “Evaluation of e-cigarettes”.
The review of the now infamous FDA report on
electronic cigarettes was done by:
Janci Chunn Lindsay, Ph.D.
Exponent Health Sciences
Toxicology and Mechanistic Biology Division
10850 Richmond Ave. Suite 175
Houston, TX 77042
July 30, 2009
It was done on behalf of NJoy, who was
one of the companies the FDA targeted with their testing. It is
important to note that NJoy is also one of the companies currently
in litigation with the FDA. The summary is below, but you can
download the entire review of the FDA’s report on e-cigarettes in
pdf here.
SUMMARY:
* The report failed to
present standard protocols for proper study design with regards to
the testing of the referenced control device, documenting the
number of samples tested
either within or across tests, or presenting statistical analyses
when quantifiable results
were obtained.
* The chemical content of similar nicotine-containing FDA-approved
products was not
completely described with respect to the presence of
tobacco-specific nitrosamines
(TSNAs) and other tobacco-associated impurities that have also
been found in nicotine
replacement therapy (NRT) devices at similar, if not higher,
levels.
* In the lots that were tested by the FDA, none of the key
chemicals of concern in this
study such as TSNAs and tobacco-associated impurities were able to
be quantifiably
measured in the liquid of NJOY’s cartridges because they were all
below the limits of
quantification (LOQ).
* All of the tobacco-associated impurities found in the NJOY
products were “present
but at less than the level of the Nicotrol® inhaler [manufacturer]
specification”
according to the FDA report.
* There is no indication in the published scientific literature
that cotinine or β-nicotyrine
are carcinogenic or have toxicity ratings of concern. These were
the only tobacco-
associated impurities found in trace levels in the vapor phase of
(some of) NJOY’s
products.
* The report does not reflect the actual dose of nicotine
delivered to the user from the
“control” Nicotrol® inhaler device when used as recommended by the
manufacturer
(6–16 cartridges/day or 24–64 mg of nicotine, 50 mcg/100 mL puff).
By comparison,
NJOY devices delivered 46 mcg/100 mL in the highest-strength
cartridge tested,
according to the FDA report.
* Data presented in the report does not adequately support the
opinion that users of
NJOY products would actually be exposed to TSNAs and
tobacco-specific impurities
in the vapor phase during normal device use; and if exposed, that
those levels would be
a health concern as compared to other FDA-approved products.
As noted in a previous about how the new tobacco
legislation effects the electronic cigarette, we noted that in order
for a product to be a drug it must be “intended
for use in the diagnosis, cure, mitigation, treatment, or prevention
of disease in man or other animals”.
And in order to be a new drug….it must be a drug.
So I contacted the
Centers for Disease Control and Prevention
(CDC) and asked if smoking was considered a disease. At first they
just sent me all the statistics about how many people smoking kills.
Then they got mad I kept asking. Then I eventually received this
response:
“When reviewing responses related to tobacco
use that were provided by CDC-INFO, we noticed your question asking if
smoking is considered a disease. As noted by CDC-INFO, smoking is a
primary risk factor for many diseases. Addiction to drugs, is viewed
as a brain disease by the
National Institute on Drug Abuse (NIDA). For information about
nicotine addiction, please visit NIDA’s Web site at
http://www.drugabuse.gov/ResearchReports/Nicotine/Nicotine.html
and
http://www.drugabuse.gov/Infofacts/understand.html”
So, according to the CDC, smoking is not a
disease, but rather it may put the user at risk of getting an actual
disease. Apparently they believe that NIDA is correct and being
addicted to nicotine is a disease. Thus, the electronic cigarette
[e-liquid] as a new drug is one that is intended to diagnosis, cure,
mitigate, treat, or prevent the addiction to nicotine. Curing nicotine
addiction would involve not using nicotine anymore.
This is why
Snus or
dissolvables
are not Nicotine Replacement Therapy (NRT) products. They are not
marketed as a way to quit smoking (quit using nicotine). They are
marketed to be used indefinitely, i.e. to continue using nicotine.
The nicotine patch or gum is meant to ween
the user off of nicotine until they no longer use it….thus curing
them. There IS a stop usage date on NRT products.
Selling a consumer an electronic cigarette as
a quit smoking device would mean it necessary to instruct the consumer
to eventually move to zero nicotine e-liquid and/or to ultimately quit
vaping altogether.
For those who think that the mere fact that
there is a zero nicotine e-liquid available means it treats nicotine
addiction; please note that there is
zero nicotine Snus
and even a
zero nicotine patch
that is apparently not an NRT, but yet does claim to help users quit
smoking (quit using nicotine). Of course no drug, means no “new drug”,
which means it isn’t a NRT.
If there is no stop usage date, then how can
an electronic cigarette cure nicotine addiction? And how can
continuing the action that got the user addicted to nicotine in the
first place help cure their addiction? If smoking / vaping / using an
electronic cigarette with zero nicotine is the cure, then so is
smoking a
zero nicotine tobacco cigarette.
Oddly enough, these nicotine free cigarettes do claim to help the user
quit smoking, but still they are not an NRT.
So we have products that contain nicotine,
have no stop usage date, and make no quit smoking claims that are not
NRTs (dissolvables, Snus)
We have products that contain no nicotine or any drugs, that do make
quit smoking claims and they are not NRTs (zero nicotine patch,
nicotine free cigarettes)
We have products that contain nicotine (or other drugs), have a stop
usage date, and claim to help users quit smoking. These are NRTs (gum,
patch, pills)
Which of these is most suitable for the
electronic cigarette? To be classified as a new drug under the
classification of a NRT, the product must 1) contain a drug and 2)
have a stop using nicotine date or imply one with the claim of
quitting smoking. Also, the American Lung Association states, “To be
most effective, nicotine replacement products should be used in
conjunction with a behavior change program.” It is pretty obvious that
electronic smoking is a continuation of the action of smoking, thus
making it a rather ineffective NRT at best.
Most reputable e-cigarette suppliers don’t
claim it helps anyone quit smoking and there is no proof that it does.
I have yet to see any manufacturer or supplier recommending a stop
usage date. It can come with nicotine or not.
So an e-cigarette that contains no nicotine
(or any other drug) and makes no quit smoking claims should be labeled
(and regulated) as an NRT? If so it would be the only product of it’s
kind.
And with nicotine e-liquid and no stop usage
date, we have a product that perpetuates nicotine addiction, not cures
it. The upside? Nicotine kills very, very, very few people (if any)
but inhaling burning tobacco kills hundreds of thousands.
BOSTON, July 27 — The FDA recently went public
with misleading information about the safety of electronic
cigarettes and the marketing of the devices, not only using its
clout but recruiting other prominent organizations to demonize a
product that has great public health benefit potential.
A group of prominent doctors and tobacco
researchers, including Dr. Michael Siegel at the Boston University
School of Public Health, Dr. Joel Nitzkin of the AAPHP Tobacco
Control Task Force, and Dr. Brad Rodu, Endowed Chair, Tobacco Harm
Reduction Research University of Louisville, challenge the FDA to
provide the full quantitative data of the study upon which the
FDA has based its warning against
electronic cigarettes. They are concerned that the FDA’s
disingenuous targeting of electronic cigarettes through a biased
presentation of the scientific data has had significant negative
impact upon the public perception of electronic cigarettes, when the
best available evidence suggests that these have shown that the
devices offer great potential to reduce serious health issues among
traditional tobacco smokers.
In a July 22 news release, the FDA cited
the detectable presence of carcinogens and “toxic chemicals” in a
“small sample” of electronic cigarette cartridges as reason for
alarm, singling out nitrosamines as particularly toxic. What the FDA
fails to inform the public is that detectable amounts of carcinogens
are also present in nicotine replacement products such as NicoDerm
CQ and Nicorette gum, both approved by the FDA, and nitrosamines
that can be also found in food items such bacon and beer. This
double standard and alarmist attitude has had the significant and
unfortunate effect of inducing hysteria among the public,
discouraging tobacco smokers from using a product which is thought
to be a significantly safer alternative to traditional tobacco.
Regrettably, the FDA has used biased
reporting of this small and inconclusive study, the complete results
of which have not been made public, to secure the vocal support of
groups such as the American Academy of Pediatrics Tobacco
Consortium, the Institute for Global Health, and the American Lung
Association in their attack on electronic cigarettes. These
researchers argue that it is absurd to consider taking electronic
cigarettes off the market when it is the conventional ones which
have been shown to be killing people. Further, the electronic
cigarette community calls for accurate and fair reporting relative
to the findings and statements of prominent medical professionals in
favor of this new and important technology and challenges the media
to tell the other side of the story.
“The FDA’s laboratory findings actually
indicate that electronic cigarettes are much, much safer than
conventional cigarettes,” says Dr. Michael Siegel. “The traces of
carcinogens present are also present in nicotine replacement
products. The FDA and the anti-smoking groups have fallen into a
huge analytical trap as they have failed to ask the appropriate
question. The question they are asking is: ‘Are electronic
cigarettes safe?’ That is not the right question. The right question
is: ‘Are electronic cigarettes much safer than traditional ones?’”
Dr. Rodu states, “The FDA tested
e-cigarettes for TSNAs using a questionable sampling regimen, and
the methods that were so sensitive that the results may have no
possible significance to users. The agency failed to report specific
levels of these contaminants, and it has failed to conduct similar
testing of nicotine medicines that have been sold in the U.S. for
over 20 years. These are not the actions of an agency that is
science-based and consumer-focused. These pseudo-scientific actions
are clearly intended to form the justification for banning a
category of products that are probably 99.9% safer than cigarettes.”
Dr. Joel Nitzkin speaking as individual
states, “The newly adopted FDA/Tobacco legislation will give full
FDA approval to currently marketed conventional cigarettes. The new
law encourages cigarette companies to produce new “reduced exposure”
cigarettes to be marketed as reduced exposure products, with no
scientific evidence that such reductions in exposure will reduce
risk of future tobacco related illness and death. In the context of
these provisions of the newly adopted FDA/Tobacco bill — FDA should
be encouraging, not maligning the manufacture and sale of electronic
cigarettes, and working with manufacturers to assure the highest
possible quality control.”
###
For more information and interviews,
contact:
Michael Siegel, MD, MPH
Professor
Department of Community Health Sciences
Boston University School of Public Health
617-638-5167
Email: mbsiegel@bu.edu
Joel L. Nitzkin, MD, MPH, DPA
Chair AAPHP Tobacco Control Task Force
Phone: 504 899 7893 or 800 598 2561
Fax: 504 899 7557
jln-md@mindspring.com
www.aaphp.org
Brad Rodu
Professor of Medicine
Endowed Chair, Tobacco Harm Reduction Research
University of Louisville
Phone: 502-561-7273
Email: brad.rodu@louisville.edu
http://rodutobaccotruth.blogspot.com
When The Smoke Clears
AILWIRE.COM, August 28, 2009 )
BOSTON Connecticut Attorney General Richard Blumenthal recently
announced plans to seek a ban on the sale of electronic cigarettes
in the state. This ill-advised decision follows a federal Food and
Drug Administration report that put a scare into electronic
cigarette users across the country, telling them that these
battery-powered devices — which deliver nicotine without burning
tobacco like conventional cigarettes — are dangerous because they
contain carcinogens.
The agency also reported that of 18 cartridges tested, one contained
diethylene glycol, an ingredient in antifreeze. The FDA threatened
to remove electronic cigarettes from the market and to take
enforcement action — including potential criml sanctions — against
product distributors.
Backed by the finding that e-cigarettes contain carcinogens and
diethylene glycol, a number of anti-smoking groups and several other
states in addition to Connecticut have jumped on the bandwagon,
considering or enacting legislation to remove these "harmful"
devices from the market.
However, the FDA failed to mention in its press conference that the
levels of tobacco-specific nitrosamines (the carcinogens) detected
in electronic cigarettes were extremely low, below the level allowed
in nicotine replacement products, such as nicotine patches, inhalers
and gum. The agency is not threatening to take nicotine patches or
gum off the market, although they too contain detectable levels of
carcinogens.
The nicotine in electronic cigarettes and FDA-approved nicotine
replacement products is derived from tobacco, which makes traces of
some tobacco carcinogens essentially inevitable.
The level of the same tobacco-specific nitrosamines in conventional
cigarettes is at least 300 to 1,400 times higher than what has been
detected in electronic cigarette cartridges. In other words, you
would have to smoke as many as 1,400 electronic cigarettes to be
potentially exposed to the same amount of these carcinogens as
smoking one conventional cigarette.
In fact, the FDA failed to perform the laboratory test of most
importance: a comparison to cigarettes which contain 57 identified
carcinogens, while e-cigarettes don't contain any carcinogens at
higher than trace levels.
The bottom line is this: Conventional cigarettes have been
thoroughly tested. They are known to contain at least 10,000
chemicals, including about 57 carcinogens. Electronic cigarettes
deliver nicotine without these 10,000 chemicals and 57 carcinogens.
It doesn't take a rocket toxicologist to figure out that electronic
cigarettes are a much, much safer alternative to conventional ones.
Unfortunately, what the FDA and the anti-smoking groups are
essentially telling smokers is that they would rather have them
continue to smoke the most toxic cigarettes — the conventional ones
— rather than switch to a product that is likely orders of magnitude
safer.
The question the FDA and the anti-smoking groups are asking is: "Are
electronic cigarettes safe?" That is not the right question. The
right question is: "Are electronic cigarettes much safer than
conventional ones?" The FDA and anti-smoking groups are comparing
electronic cigarettes to a solution of spring-fresh Maine mountain
stream water. What they need to compare electronic cigarettes to is
a Marlboro cigarette. This doesn't mean that there aren't problems
with e-cigarettes that need to be addressed. This doesn't mean
e-cigarette manufacturers shouldn't be asked to make certain
changes, such as instituting tighter quality control procedures and
making sure the propylene glycol void of diethylene glycol. This
doesn't mean that there shouldn't be restrictions on the sale of
these devices to minors.
But it does mean that it is lunacy to ban the product, especially
given that the very same FDA is now approving deadly Marlboros,
Winstons, Kools, Newports, Camels
The FDA and anti-smoking groups are on the verge of losing sight of
the actual objective of public health regulation: to improve the
overall population's health. The combination of FDA approval of
conventional cigarettes and FDA banning of the much safer electronic
ones would be ludicrous, would have detrimental population health
effects and would send exactly the wrong message to the public.
The real threat to our children's health is not electronic
cigarettes. It's the real ones.
(This commentary originally appeared in the Hartford Courant.)
- - - - - - - - - -
Dr. Michael Siegel is associate chairman and a professor in the
Department of Community Health Sciences at Boston University. He is
a physician who completed his residency in Preventive Medicine at
the UC Berkeley School of Public Health and trained in epidemiology
for two years at the Centers for Disease Control and Prevention in
Atlanta before coming to Boston. With more than 20 years of
experience in tobacco control, primarily as a researcher, Dr.
Siegel’s primary interest is in the area of tobacco control,
focusing on secondhand smoke health effects, exposure, and policies,
cigarette advertising and marketing practices and their effects on
youths, and evaluation of tobacco control policies and their impact
on youth and adult smoking behavior. His primary teaching is in the
areas of mass communication, marketing, and public health advocacy.
He is co-author of a book, entitled “Marketing Public Health:
Strategies to Promote Social Change” and has been active in
promoting smoke-free bar and restaurant policies throughout the
country. Dr. Siegel has served as an expert witness in several major
tobacco litigation cases.
His research and writing on tobacco issues can be read at
http://tobaccoanalysis.blogspot.com/
His profile can be seen at
http://sph.bu.edu/index.php?option=com_sphdir&id=239&Itemid=340&INDEX=677
Tobacco Control Expert Dr. Michael Siegel
Calls for a Scientific, Not Ideological or Political Response to the
Electronic Cigarette Issue
(EMAILWIRE., September 08, 2009 ) BOSTON –
An article in this week's issue of the Journal of the American
Medical Association (JAMA) reports that the Food and Drug
Administration (FDA) has now acknowledged receiving 98 reports of
suicides and 188 reports of suicide attempts that appear to be
linked to use of Chantix, a prescription medication for smoking
cessation. In addition, the FDA has received reports of patients
taking the drug being involved in motor vehicle crashes.
At the same time, the FDA which has approved Chantix, seems
focused on keeping electronic cigarettes, which have yet to be
proven harmful, from the public.
A growing number of tobacco control experts and medical
professionals are questioning the motives of the FDA. Dr. Michael
Siegel, associate chairman and a professor in the Department of
Community Health Sciences at the Boston University School of
Public Health, wonders why the FDA is threatening to take
electronic cigarettes off the market.
“If
Chantix has
been studied and has been found to have likely caused 98 deaths
and an additional 188 attempted suicides and it is allowed to
remain on the market because smoking cessation is such an
important goal, then what is the point of removing e-cigarettes
from the market while studying its potential adverse effects?
Suppose e-cigarettes were to be found to have caused 100 deaths.
Would that warrant taking it off the market, since it - like
Chantix - is helping people to quit smoking?” Dr. Siegel asks in a
statement released by the Center for Public Accountability in
Tobacco Control.
According to the JAMA article: "Although varenicline’s label had
already indicated potential psychiatric risks, the agency has
continued to receive reports of attempted and completed suicide in
varenicline-treated patients, including some who had no history of
psychiatric problems. An FDA analysis, released earlier this year,
of varenicline adverse event reports submitted to the agency
between May 2006 and November 2007 documented 19 suicides and 18
reports of suicidal behaviors, including 15 suicide attempts...
But at a press briefing in July, Rosebraugh said that based on
crude counts the agency now has reports of 98 suicides and 188
suicide attempts."
The
JAMA article
also notes that the FDA is requiring Pfizer, the makers of
Chantix, to conduct clinical studies to determine the incidence
and severity of the adverse effects of Chantix: "To better
understand the incidence of these adverse events and which
patients may be at greatest risk, the FDA is requiring the
manufacturers of both drugs to conduct additional randomized
controlled trials. Unlike previous studies, these trials will
include individuals with preexisting mental health conditions,
who make up a disproportionate number of smokers."
Siegel notes that unlike Chantix - for which there were many
immediate post-marketing reports of potential adverse effects --
e-cigarettes have been on the market for more than three years
and there have yet to be any severe adverse effects reported.
“In other words, we know that people are dying from taking
Chantix but we're going to allow it to remain on the market
because it's helping people to quit smoking. We know that there
is no evidence that anyone is dying from using electronic
cigarettes, but we're going to take them off the market, even
though they are helping people to quit smoking. That just
doesn't make any sense,” Dr. Siegel said.
Another thing that troubles Dr. Siegel is why anti-smoking
groups are calling for the removal of e-cigarettes from the
market, “when we are not aware of any documented severe adverse
effects, yet they are not calling for the removal of Chantix
from the market even though we know this drug is probably
killing people.”
One answer, he believes, is the heavy financial influence of the
pharmaceutical industry. “So far, every anti-smoking group which
has called for the removal of e-cigarettes from the market has
been found to be financially tied to Big Pharma. The Campaign
for Tobacco-Free Kids, American Cancer Society, American Heart
Association, American Lung Association, and Action on Smoking
and Health have all received funding of some sort from the
pharmaceutical industry. None of these groups, however,
disclosed their financial conflicts of interest when they called
for a ban on electronic cigarettes.”
On September 2, Pfizer was fined $2.3 billion by Federal
prosecutors for illegal drug promotion. Authorities called
Pfizer a repeat offender, citing this was the fourth such
settlement in the past ten years.
Dr. Siegel is concerned that the one constituency not being
represented here is the public, which would want a reasonable
alternative to products that are known to cause harm.
“I believe that not only are the actions of these groups
inappropriate, unsupported by science, harmful to the public's
health, and heavily biased due to financial relationships, but
these actions are also unethical because it is unscrupulous to
advocate for a public policy like this without revealing such an
important and relevant financial conflict of interest,” Dr.
Siegel said.
Dr.
Michael Siegel
is associate chairman and a professor in the Department of
Community Health Sciences at Boston University. He is a
physician who completed his residency in Preventive Medicine at
the UC Berkeley School of Public Health and trained in
epidemiology for two years at the Centers for Disease Control
and Prevention in Atlanta before coming to Boston. With more
than 20 years of experience in tobacco control, primarily as a
researcher, Dr. Siegel’s primary interest is in the area of
tobacco control, focusing on secondhand smoke health effects,
exposure, and policies, cigarette advertising and marketing
practices and their effects on youths, and evaluation of tobacco
control policies and their impact on youth and adult smoking
behavior. His primary teaching is in the areas of mass
communication, marketing, and public health advocacy. He is
co-author of a book, entitled “Marketing Public Health:
Strategies to Promote Social Change” and has been active in
promoting smoke-free bar and restaurant policies throughout the
country. Dr. Siegel has served as an expert witness in several
major tobacco litigation cases. His research and writing on
tobacco issues can be read at
http://tobaccoanalysis.blogspot.com/.
|
|